<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8699062
   </pmid>
   <datecreated>
    <year>
     1996
    </year>
    <month>
     09
    </month>
    <day>
     05
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1996
    </year>
    <month>
     09
    </month>
    <day>
     05
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0022-1899
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       174
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        1996
       </year>
       <month>
        Aug
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of infectious diseases
     </title>
     <isoabbreviation>
      J. Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study.
    </articletitle>
    <pagination>
     <medlinepgn>
      324-31
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Ninety-four patients with infectious mononucleosis and symptoms &lt; or = 7 days were randomized to treatment with oral acyclovir (800 mg 5 times/day) and prednisolone (0.7 mg/kg for the first 4 days, which was reduced by 0.1 mg/kg on consecutive days for another 6 days; n = 48), or placebo (n = 46) for 10 days. Oropharyngeal Epstein-Barr virus (EBV) shedding was significantly inhibited during the treatment period (P = .02, Mann-Whitney rank test). No significant effect was observed for duration of general illness, sore throat, weight loss, or absence from school or work. The frequency of latent EBV-infected B lymphocytes in peripheral blood and the HLA-restricted EBV-specific cellular immunity, measured 6 months after onset of disease, was not affected by treatment. Thus, acyclovir combined with prednisolone inhibited oropharyngeal EBV replication without affecting duration of clinical symptoms or development of EBV-specific cellular immunity.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Infectious Diseases, Karolinska Institutet, Danderyd, Sweden.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Tynell
      </lastname>
      <forename>
       E
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Aurelius
      </lastname>
      <forename>
       E
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Brandell
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Julander
      </lastname>
      <forename>
       I
      </forename>
      <initials>
       I
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wood
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Yao
      </lastname>
      <forename>
       Q Y
      </forename>
      <initials>
       QY
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rickinson
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Akerlund
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Andersson
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Controlled Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Infect Dis
    </medlineta>
    <nlmuniqueid>
     0413675
    </nlmuniqueid>
    <issnlinking>
     0022-1899
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antibodies, Viral
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antiviral Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Glucocorticoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      HLA Antigens
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Placebos
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-24-8
     </registrynumber>
     <nameofsubstance>
      Prednisolone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      59277-89-3
     </registrynumber>
     <nameofsubstance>
      Acyclovir
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acyclovir
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antibodies, Viral
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antiviral Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glucocorticoids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Great Britain
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      HLA Antigens
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Herpesvirus 4, Human
     </descriptorname>
     <qualifiername majortopicyn="N">
      isolation &amp; purification
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunity, Cellular
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Infectious Mononucleosis
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pharyngitis
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Placebos
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prednisolone
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Safety
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Saliva
     </descriptorname>
     <qualifiername majortopicyn="N">
      virology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Sweden
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1996
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1996
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1996
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8699062
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

